Cecilia Brown

DocwireNews

The US Food and Drug Administration has approved amivantamab-vmjw (Rybrevant, Janssen Biotech, Inc.) plus carboplatin and pemetrexed for adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 L858R substitution mutations. The approval is for patients whose disease has progressed on or after treatment with an EGFR tyrosine kinase inhibitor.
The efficacy was evaluated in the randomized, open-label, multicenter MARIPOSA-2 trial. The trial included 657 patients who had locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations. All patients had disease progression on or after receiving osimertinib. The study investigators randomized patients 1:2:2 to receive amivantamab-vmjw with carboplatin and pemetrexed, carboplatin and pemetrexed, or amivantamab-vmjw as part of another combination regimen.
The primary efficacy outcome measure in MARIPOSA was progression-free survival (PFS) as assessed by a blinded independent central review for the comparison between amivantamab plus carboplatin and pemetrexed versus carboplatin and pemetrexed. The median PFS was 6.3 months in patients receiving amivantamab plus carboplatin and pemetrexed, significantly longer than the median PFS in those receiving carboplatin and pemetrexed (hazard ratio [HR] 0.48; P&lt;.0001).
The confirmed overall response rate was 55% in patients receiving amivantamab plus carboplatin and pemetrexed, compared with 29% in those receiving carboplatin and pemetrexed (P&lt;.0001). No statistically significant difference was observed in overall survival (OS) between the two groups at the prespecified second interim analysis of OS. The stratified OS HR was 0.73.
The most common adverse reactions, occurring in at least 20% of patients, were rash, infusion-related reactions, fatigue, nail toxicity, nausea, constipation, edema, stomatitis, decreased appetite, musculoskeletal pain, vomiting, and COVID-19 infection.
The recommended amivantamab-vmjw dose is based on baseline body weight. Full prescribing information will be posted on <a href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm">Drugs@FDA</a>.
Source: <a href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-amivantamab-vmjw-carboplatin-and-pemetrexed-non-small-cell-lung-cancer-egfr-exon-19">FDA</a>

Emily Menendez

177Lu-edotreotide Improves PFS, OS Over Everolimus for SSTR-Positive GEP-NETs

GEP-NETs

MATTERHORN: Durvalumab Plus FLOT Improves EFS and pCR in Gastric, GEJ Cancers

Gastroesophageal Cancer

Risk for Choledocholithiasis Higher in Older Adult Patients With Cholangiocarcinoma

Bile Duct Cancer

Latest News

FDA Approves Amivantamab Plus Carboplatin, Pemetrexed for Certain Patients With NSCLC

EGFR+ NSCLC

The US FDA approved amivantamab-vmjw (Rybrevant, Janssen Biotech, Inc.) plus carboplatin and pemetrexed for adults with locally advanced or metastatic non-small cell lung cancer.

FDA Approves Amivantamab Plus Carboplatin, Pemetrexed For Certain Patients With NSCLC

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Colorectal Cancer

Gastric Cancer

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

Mesothelioma

Non-Small Cell Lung Cancer

Small Cell Lung Cancer

Lung Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe